A Rodríguez1,2,3, J Gómez-Ambrosi1,2,3, V Catalán1,2,3, S Ezquerro1,2,3, L Méndez-Giménez1,2,3, S Becerril1,2,3, P Ibáñez2,3,4, N Vila2,3,4, M A Margall2,3,4, R Moncada2,3,5, V Valentí2,3,6, C Silva2,3,4, J Salvador2,4, G Frühbeck1,2,3,4. 1. Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain. 2. CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain. 3. Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. 4. Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain. 5. Department of Anesthesia, Clínica Universidad de Navarra, Pamplona, Spain. 6. Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
Abstract
BACKGROUND/ OBJECTIVES: Uroguanylin and guanylin are secreted by intestinal epithelial cells as prohormones postprandially and act on the hypothalamus to induce satiety. The impact of obesity and obesity-associated type 2 diabetes (T2D) on proguanylin and prouroguanylin expression/secretion as well as the potential role of guanylin and uroguanylin in the control of lipolysis in humans was evaluated. SUBJECTS/ METHODS: Circulating and gastrointestinal expression of proguanylin (GUCA2A) and prouroguanylin (GUCA2B) were measured in 134 subjects. In addition, plasma proguanylin and prouroguanylin were measured before and after weight loss achieved either by Roux-en-Y gastric bypass (RYGB) (n=24) or after a conventional diet (n=15). The effect of guanylin and uroguanylin (1-100 nmol l(-1)) on lipolysis was determined in vitro in omental adipocytes. RESULTS: Circulating concentrations of prouroguanylin, but not proguanylin, were decreased in obesity in relation to adiposity. Weight loss achieved by RYGB increased plasma proguanylin and prouroguanylin. Obese T2D individuals showed higher expression of intestinal GUCA2A as well as of the receptors of the guanylin system, GUCY2C and GUCY2D, in omental adipocytes. The incubation with guanylin and uroguanylin significantly stimulated lipolysis in differentiated omental adipocytes, as evidenced by hormone-sensitive lipase phosphorylation at Ser563, an increase in fatty acids and glycerol release together with an upregulation of several lipolysis-related genes, including AQP3, AQP7, FATP1 or CD36. CONCLUSIONS: Both guanylin and uroguanylin trigger lipolysis in human visceral adipocytes. Given the lipolytic action of the guanylin system on visceral adipocytes, the herein reported decrease of circulating prouroguanylin concentrations in obese patients may have a role in excessive fat accumulation in obesity.
BACKGROUND/ OBJECTIVES:Uroguanylin and guanylin are secreted by intestinal epithelial cells as prohormones postprandially and act on the hypothalamus to induce satiety. The impact of obesity and obesity-associated type 2 diabetes (T2D) on proguanylin and prouroguanylin expression/secretion as well as the potential role of guanylin and uroguanylin in the control of lipolysis in humans was evaluated. SUBJECTS/ METHODS: Circulating and gastrointestinal expression of proguanylin (GUCA2A) and prouroguanylin (GUCA2B) were measured in 134 subjects. In addition, plasma proguanylin and prouroguanylin were measured before and after weight loss achieved either by Roux-en-Y gastric bypass (RYGB) (n=24) or after a conventional diet (n=15). The effect of guanylin and uroguanylin (1-100 nmol l(-1)) on lipolysis was determined in vitro in omental adipocytes. RESULTS: Circulating concentrations of prouroguanylin, but not proguanylin, were decreased in obesity in relation to adiposity. Weight loss achieved by RYGB increased plasma proguanylin and prouroguanylin. Obese T2D individuals showed higher expression of intestinal GUCA2A as well as of the receptors of the guanylin system, GUCY2C and GUCY2D, in omental adipocytes. The incubation with guanylin and uroguanylin significantly stimulated lipolysis in differentiated omental adipocytes, as evidenced by hormone-sensitive lipase phosphorylation at Ser563, an increase in fatty acids and glycerol release together with an upregulation of several lipolysis-related genes, including AQP3, AQP7, FATP1 or CD36. CONCLUSIONS: Both guanylin and uroguanylin trigger lipolysis in human visceral adipocytes. Given the lipolytic action of the guanylin system on visceral adipocytes, the herein reported decrease of circulating prouroguanylin concentrations in obesepatients may have a role in excessive fat accumulation in obesity.
Authors: Dequan Zhou; Dmitri Samovski; Adewole L Okunade; Philip D Stahl; Nada A Abumrad; Xiong Su Journal: FASEB J Date: 2012-07-19 Impact factor: 5.191
Authors: C Folgueira; E Sanchez-Rebordelo; S Barja-Fernandez; R Leis; S Tovar; F F Casanueva; C Dieguez; R Nogueiras; L M Seoane Journal: Eur J Nutr Date: 2015-03-06 Impact factor: 5.614
Authors: Michael A Valentino; Jieru E Lin; Adam E Snook; Peng Li; Gilbert W Kim; Glen Marszalowicz; Michael S Magee; Terry Hyslop; Stephanie Schulz; Scott A Waldman Journal: J Clin Invest Date: 2011-08-25 Impact factor: 14.808
Authors: Jean L Chan; Edward C Mun; Violeta Stoyneva; Christos S Mantzoros; Allison B Goldfine Journal: Obesity (Silver Spring) Date: 2006-02 Impact factor: 5.002
Authors: A Rodríguez; J Gómez-Ambrosi; V Catalán; M J Gil; S Becerril; N Sáinz; C Silva; J Salvador; I Colina; G Frühbeck Journal: Int J Obes (Lond) Date: 2009-02-24 Impact factor: 5.095
Authors: Coralie Sengenes; Anne Bouloumie; Hans Hauner; Michel Berlan; Rudi Busse; Max Lafontan; Jean Galitzky Journal: J Biol Chem Date: 2003-09-10 Impact factor: 5.157
Authors: D J Merlino; J R Barton; B A Charsar; M D Byrne; J A Rappaport; R J Smeyne; A C Lepore; A E Snook; S A Waldman Journal: Brain Struct Funct Date: 2019-09-04 Impact factor: 3.270
Authors: Matthew D Di Guglielmo; Dalal Tonb; Zhaoping He; Adebowale Adeyemi; Kenneth L van Golen Journal: J Pediatr Gastroenterol Nutr Date: 2018-03 Impact factor: 2.839
Authors: Nikola Habek; Marina Dobrivojević Radmilović; Milan Kordić; Katarina Ilić; Sandra Grgić; Vladimir Farkaš; Robert Bagarić; Siniša Škokić; Alfred Švarc; Aleksandra Dugandžić Journal: Pflugers Arch Date: 2020-01-15 Impact factor: 3.657
Authors: Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman Journal: Expert Rev Precis Med Drug Dev Date: 2021-02-02
Authors: Hilde L von Volkmann; Ingeborg Brønstad; Odd Helge Gilja; Rune R Tronstad; Dag Andre Sangnes; Ragnar Nortvedt; Trygve Hausken; Georg Dimcevski; Torunn Fiskerstrand; Kim Nylund Journal: PLoS One Date: 2017-09-28 Impact factor: 3.240
Authors: Scott A Waldman; Renata Tenenbaum; Henry C Foehl; Peter Winkle; Patrick Griffin Journal: Clin Transl Gastroenterol Date: 2019-07 Impact factor: 4.488